Zyngenia

Zyngenia is a privately held biotherapeutics company that develops multi-specific antibody-derived drugs. It uses proprietary technology to develop differentiated mAb-based therapeutics called 'Zybodies'. Its pipeline is comprised of mAb-based drugs that are able to concomitantly engage several validated disease targets through the genetic fusion of additional peptide binding motifs to the mAb. It has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific programs in cancer and inflammation.